Tiziana Life Sciences Ltd.: Tiziana Life Sciences Completes

Tiziana Life Sciences Ltd.: Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel

Related Keywords

Boston , Massachusetts , United States , Irina Koffler , Hana Malik , Gabriele Cerrone , Tiziana Life Sciences , Lifesci Advisors , Tiziana Life Sciences Ltd , Patient Population Expanded Access Program , Nasdaq , Business Development , Life Sciences , Secondary Progressive Multiple Sclerosis , Executive Chairman , Chief Executive Officer , Investor Relations , Sci Advisors , Tiziana , Life , Ciences , Ompletes , Enrollment , First , Patient , Cohort , Intermediate , Size , Population , Xpanded , Access , Program , Valuate , Foralumab , Ctive , Secondary , Multiple , Clerosis , Patients ,